Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study

NCT06868030 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease
MCI-AD, Early Stage Alzheimer's Disease

Sponsor

First Hospital of China Medical University